Global Gastrointestinal Stromal Tumor Drug Market Research Report 2024

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

The global Gastrointestinal Stromal Tumor Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Gastrointestinal Stromal Tumor Drug include Novartis, Bayer Pharmaceuticals, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals, Actavis Generics, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., Apotex Inc., Mylan Pharms Inc., Bulat Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Gastrointestinal Stromal Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Stromal Tumor Drug.

The Gastrointestinal Stromal Tumor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Gastrointestinal Stromal Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. 
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Gastrointestinal Stromal Tumor Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gastrointestinal Stromal Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3:  Sales, revenue of Gastrointestinal Stromal Tumor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report. 

 1 Gastrointestinal Stromal Tumor Drug Market Overview
    1.1 Product Definition
    1.2 Gastrointestinal Stromal Tumor Drug by Type
        1.2.1 Global Gastrointestinal Stromal Tumor Drug Market Value Comparison by Type (2024-2030)
        1.2.2 Imatinib
        1.2.3 Sunitinib
        1.2.4 Regorafenib
        1.2.5 Ripretinib
        1.2.6 Others
    1.3 Gastrointestinal Stromal Tumor Drug by Application
        1.3.1 Global Gastrointestinal Stromal Tumor Drug Market Value by Application (2024-2030)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Global Gastrointestinal Stromal Tumor Drug Market Size Estimates and Forecasts
        1.4.1 Global Gastrointestinal Stromal Tumor Drug Revenue 2019-2030
        1.4.2 Global Gastrointestinal Stromal Tumor Drug Sales 2019-2030
        1.4.3 Global Gastrointestinal Stromal Tumor Drug Market Average Price (2019-2030)
    1.5 Assumptions and Limitations

 2 Gastrointestinal Stromal Tumor Drug Market Competition by Manufacturers
    2.1 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Manufacturers (2019-2024)
    2.2 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Manufacturers (2019-2024)
    2.3 Global Gastrointestinal Stromal Tumor Drug Average Price by Manufacturers (2019-2024)
    2.4 Global Key Players of Gastrointestinal Stromal Tumor Drug, Industry Ranking, 2022 VS 2023 VS 2024
    2.5 Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Manufacturing Sites & Headquarters
    2.6 Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Product Type & Application
    2.7 Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Date of Enter into This Industry
    2.8 Global Gastrointestinal Stromal Tumor Drug Market Competitive Situation and Trends
        2.8.1 Global Gastrointestinal Stromal Tumor Drug Market Concentration Rate
        2.8.2 The Global 5 and 10 Largest Gastrointestinal Stromal Tumor Drug Players Market Share by Revenue
        2.8.3 Global Gastrointestinal Stromal Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

 3 Global Gastrointestinal Stromal Tumor Drug Market Scenario by Region
    3.1 Global Gastrointestinal Stromal Tumor Drug Market Size by Region: 2019 Versus 2023 Versus 2030
    3.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2019-2030
        3.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2019-2024
        3.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2025-2030
    3.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2019-2030
        3.3.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2019-2024
        3.3.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2025-2030
    3.4 North America Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
        3.4.1 North America Gastrointestinal Stromal Tumor Drug Market Size by Country: 2019 VS 2023 VS 2030
        3.4.2 North America Gastrointestinal Stromal Tumor Drug Sales by Country (2019-2030)
        3.4.3 North America Gastrointestinal Stromal Tumor Drug Revenue by Country (2019-2030)
        3.4.4 United States
        3.4.5 Canada
    3.5 Europe Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
        3.5.1 Europe Gastrointestinal Stromal Tumor Drug Market Size by Country: 2019 VS 2023 VS 2030
        3.5.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2019-2030)
        3.5.3 Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (2019-2030)
        3.5.4 Germany
        3.5.5 France
        3.5.6 U.K.
        3.5.7 Italy
        3.5.8 Russia
    3.6 Asia Pacific Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Region
        3.6.1 Asia Pacific Gastrointestinal Stromal Tumor Drug Market Size by Region: 2019 VS 2023 VS 2030
        3.6.2 Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Region (2019-2030)
        3.6.3 Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region (2019-2030)
        3.6.4 China
        3.6.5 Japan
        3.6.6 South Korea
        3.6.7 India
        3.6.8 Australia
        3.6.9 China Taiwan
        3.6.10 Southeast Asia
    3.7 Latin America Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
        3.7.1 Latin America Gastrointestinal Stromal Tumor Drug Market Size by Country: 2019 VS 2023 VS 2030
        3.7.2 Latin America Gastrointestinal Stromal Tumor Drug Sales by Country (2019-2030)
        3.7.3 Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country
        3.7.4 Mexico
        3.7.5 Brazil
        3.7.6 Argentina
        3.7.7 Colombia
    3.8 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Facts & Figures by Country
        3.8.1 Middle East and Africa Gastrointestinal Stromal Tumor Drug Market Size by Country: 2019 VS 2023 VS 2030
        3.8.2 Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2019-2030)
        3.8.3 Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country
        3.8.4 Turkey
        3.8.5 Saudi Arabia
        3.8.6 UAE

 4 Segment by Type
    4.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2019-2030)
        4.1.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2019-2024)
        4.1.2 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2025-2030)
        4.1.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2019-2030)
    4.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2019-2030)
        4.2.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2019-2024)
        4.2.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2025-2030)
        4.2.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2019-2030)
    4.3 Global Gastrointestinal Stromal Tumor Drug Price by Type (2019-2030)

 5 Segment by Application
    5.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2019-2030)
        5.1.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2019-2024)
        5.1.2 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2025-2030)
        5.1.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2019-2030)
    5.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2019-2030)
        5.2.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2019-2024)
        5.2.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2025-2030)
        5.2.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2019-2030)
    5.3 Global Gastrointestinal Stromal Tumor Drug Price by Application (2019-2030)

 6 Key Companies Profiled
    6.1 Novartis
        6.1.1 Novartis Company Information
        6.1.2 Novartis Description and Business Overview
        6.1.3 Novartis Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.1.4 Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.1.5 Novartis Recent Developments/Updates
    6.2 Bayer Pharmaceuticals
        6.2.1 Bayer Pharmaceuticals Company Information
        6.2.2 Bayer Pharmaceuticals Description and Business Overview
        6.2.3 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.2.4 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.2.5 Bayer Pharmaceuticals Recent Developments/Updates
    6.3 Glenmark Pharmaceuticals Ltd.
        6.3.1 Glenmark Pharmaceuticals Ltd. Company Information
        6.3.2 Glenmark Pharmaceuticals Ltd. Description and Business Overview
        6.3.3 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.3.4 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.3.5 Glenmark Pharmaceuticals Ltd. Recent Developments/Updates
    6.4 Sun Pharmaceuticals
        6.4.1 Sun Pharmaceuticals Company Information
        6.4.2 Sun Pharmaceuticals Description and Business Overview
        6.4.3 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.4.4 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.4.5 Sun Pharmaceuticals Recent Developments/Updates
    6.5 Actavis Generics
        6.5.1 Actavis Generics Company Information
        6.5.2 Actavis Generics Description and Business Overview
        6.5.3 Actavis Generics Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.5.4 Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.5.5 Actavis Generics Recent Developments/Updates
    6.6 Dr. Reddy's Laboratories
        6.6.1 Dr. Reddy's Laboratories Company Information
        6.6.2 Dr. Reddy's Laboratories Description and Business Overview
        6.6.3 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.6.4 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.6.5 Dr. Reddy's Laboratories Recent Developments/Updates
    6.7 Teva Pharmaceutical Industries Ltd.
        6.7.1 Teva Pharmaceutical Industries Ltd. Company Information
        6.7.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
        6.7.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.7.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
    6.8 Apotex Inc.
        6.8.1 Apotex Inc. Company Information
        6.8.2 Apotex Inc. Description and Business Overview
        6.8.3 Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.8.4 Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.8.5 Apotex Inc. Recent Developments/Updates
    6.9 Mylan Pharms Inc.
        6.9.1 Mylan Pharms Inc. Company Information
        6.9.2 Mylan Pharms Inc. Description and Business Overview
        6.9.3 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.9.4 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.9.5 Mylan Pharms Inc. Recent Developments/Updates
    6.10 Bulat Pharmaceutical
        6.10.1 Bulat Pharmaceutical Company Information
        6.10.2 Bulat Pharmaceutical Description and Business Overview
        6.10.3 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.10.4 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.10.5 Bulat Pharmaceutical Recent Developments/Updates
    6.11 MSN Laboratories
        6.11.1 MSN Laboratories Company Information
        6.11.2 MSN Laboratories Description and Business Overview
        6.11.3 MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.11.4 MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.11.5 MSN Laboratories Recent Developments/Updates
    6.12 Vannsh Life Sciences
        6.12.1 Vannsh Life Sciences Company Information
        6.12.2 Vannsh Life Sciences Description and Business Overview
        6.12.3 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.12.4 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.12.5 Vannsh Life Sciences Recent Developments/Updates
    6.13 Beacon Pharmaceuticals
        6.13.1 Beacon Pharmaceuticals Company Information
        6.13.2 Beacon Pharmaceuticals Description and Business Overview
        6.13.3 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.13.4 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.13.5 Beacon Pharmaceuticals Recent Developments/Updates
    6.14 Drug International
        6.14.1 Drug International Company Information
        6.14.2 Drug International Description and Business Overview
        6.14.3 Drug International Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.14.4 Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.14.5 Drug International Recent Developments/Updates
    6.15 Deciphera Pharmaceuticals
        6.15.1 Deciphera Pharmaceuticals Company Information
        6.15.2 Deciphera Pharmaceuticals Description and Business Overview
        6.15.3 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.15.4 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.15.5 Deciphera Pharmaceuticals Recent Developments/Updates
    6.16 CSPC Pharmaceuticals
        6.16.1 CSPC Pharmaceuticals Company Information
        6.16.2 CSPC Pharmaceuticals Description and Business Overview
        6.16.3 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.16.4 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.16.5 CSPC Pharmaceuticals Recent Developments/Updates
    6.17 Hansoh Pharmaceuticals
        6.17.1 Hansoh Pharmaceuticals Company Information
        6.17.2 Hansoh Pharmaceuticals Description and Business Overview
        6.17.3 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.17.4 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.17.5 Hansoh Pharmaceuticals Recent Developments/Updates
    6.18 Kelun Pharmaceuticals
        6.18.1 Kelun Pharmaceuticals Company Information
        6.18.2 Kelun Pharmaceuticals Description and Business Overview
        6.18.3 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.18.4 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.18.5 Kelun Pharmaceuticals Recent Developments/Updates
    6.19 Zai Lab
        6.19.1 Zai Lab Company Information
        6.19.2 Zai Lab Description and Business Overview
        6.19.3 Zai Lab Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.19.4 Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.19.5 Zai Lab Recent Developments/Updates
    6.20 CStone Pharmaceuticals
        6.20.1 CStone Pharmaceuticals Company Information
        6.20.2 CStone Pharmaceuticals Description and Business Overview
        6.20.3 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.20.4 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.20.5 CStone Pharmaceuticals Recent Developments/Updates
    6.21 China Biopharmaceuticals
        6.21.1 China Biopharmaceuticals Company Information
        6.21.2 China Biopharmaceuticals Description and Business Overview
        6.21.3 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
        6.21.4 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
        6.21.5 China Biopharmaceuticals Recent Developments/Updates

 7 Industry Chain and Sales Channels Analysis
    7.1 Gastrointestinal Stromal Tumor Drug Industry Chain Analysis
    7.2 Gastrointestinal Stromal Tumor Drug Key Raw Materials
        7.2.1 Key Raw Materials
        7.2.2 Raw Materials Key Suppliers
    7.3 Gastrointestinal Stromal Tumor Drug Production Mode & Process
    7.4 Gastrointestinal Stromal Tumor Drug Sales and Marketing
        7.4.1 Gastrointestinal Stromal Tumor Drug Sales Channels
        7.4.2 Gastrointestinal Stromal Tumor Drug Distributors
    7.5 Gastrointestinal Stromal Tumor Drug Customers

 8 Gastrointestinal Stromal Tumor Drug Market Dynamics
    8.1 Gastrointestinal Stromal Tumor Drug Industry Trends
    8.2 Gastrointestinal Stromal Tumor Drug Market Drivers
    8.3 Gastrointestinal Stromal Tumor Drug Market Challenges
    8.4 Gastrointestinal Stromal Tumor Drug Market Restraints

 9 Research Findings and Conclusion

 10 Methodology and Data Source
    10.1 Methodology/Research Approach
        10.1.1 Research Programs/Design
        10.1.2 Market Size Estimation
        10.1.3 Market Breakdown and Data Triangulation
    10.2 Data Source
        10.2.1 Secondary Sources
        10.2.2 Primary Sources
    10.3 Author List
    10.4 Disclaimer

List of Tables
 Table 1. Global Gastrointestinal Stromal Tumor Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Gastrointestinal Stromal Tumor Drug Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Gastrointestinal Stromal Tumor Drug Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Gastrointestinal Stromal Tumor Drug Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Gastrointestinal Stromal Tumor Drug Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Gastrointestinal Stromal Tumor Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Gastrointestinal Stromal Tumor Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Gastrointestinal Stromal Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastrointestinal Stromal Tumor Drug as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Gastrointestinal Stromal Tumor Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2019-2024) & (K Units)
 Table 18. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2019-2024)
 Table 19. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2025-2030) & (K Units)
 Table 20. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2025-2030)
 Table 21. Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2019-2024)
 Table 23. Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2025-2030)
 Table 25. North America Gastrointestinal Stromal Tumor Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Gastrointestinal Stromal Tumor Drug Sales by Country (2019-2024) & (K Units)
 Table 27. North America Gastrointestinal Stromal Tumor Drug Sales by Country (2025-2030) & (K Units)
 Table 28. North America Gastrointestinal Stromal Tumor Drug Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Gastrointestinal Stromal Tumor Drug Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Gastrointestinal Stromal Tumor Drug Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Gastrointestinal Stromal Tumor Drug Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Gastrointestinal Stromal Tumor Drug Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Gastrointestinal Stromal Tumor Drug Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Type (2019-2024)
 Table 51. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Type (2025-2030)
 Table 52. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2019-2024)
 Table 53. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2025-2030)
 Table 54. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2019-2024)
 Table 57. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2025-2030)
 Table 58. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Application (2019-2024)
 Table 61. Global Gastrointestinal Stromal Tumor Drug Sales (K Units) by Application (2025-2030)
 Table 62. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2019-2024)
 Table 63. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2025-2030)
 Table 64. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Gastrointestinal Stromal Tumor Drug Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2019-2024)
 Table 67. Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2025-2030)
 Table 68. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Application (2025-2030)
 Table 70. Novartis Company Information
 Table 71. Novartis Description and Business Overview
 Table 72. Novartis Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Novartis Gastrointestinal Stromal Tumor Drug Product
 Table 74. Novartis Recent Developments/Updates
 Table 75. Bayer Pharmaceuticals Company Information
 Table 76. Bayer Pharmaceuticals Description and Business Overview
 Table 77. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
 Table 79. Bayer Pharmaceuticals Recent Developments/Updates
 Table 80. Glenmark Pharmaceuticals Ltd. Company Information
 Table 81. Glenmark Pharmaceuticals Ltd. Description and Business Overview
 Table 82. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product
 Table 84. Glenmark Pharmaceuticals Ltd. Recent Developments/Updates
 Table 85. Sun Pharmaceuticals Company Information
 Table 86. Sun Pharmaceuticals Description and Business Overview
 Table 87. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
 Table 89. Sun Pharmaceuticals Recent Developments/Updates
 Table 90. Actavis Generics Company Information
 Table 91. Actavis Generics Description and Business Overview
 Table 92. Actavis Generics Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Actavis Generics Gastrointestinal Stromal Tumor Drug Product
 Table 94. Actavis Generics Recent Developments/Updates
 Table 95. Dr. Reddy's Laboratories Company Information
 Table 96. Dr. Reddy's Laboratories Description and Business Overview
 Table 97. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product
 Table 99. Dr. Reddy's Laboratories Recent Developments/Updates
 Table 100. Teva Pharmaceutical Industries Ltd. Company Information
 Table 101. Teva Pharmaceutical Industries Ltd. Description and Business Overview
 Table 102. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product
 Table 104. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
 Table 105. Apotex Inc. Company Information
 Table 106. Apotex Inc. Description and Business Overview
 Table 107. Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Apotex Inc. Gastrointestinal Stromal Tumor Drug Product
 Table 109. Apotex Inc. Recent Developments/Updates
 Table 110. Mylan Pharms Inc. Company Information
 Table 111. Mylan Pharms Inc. Description and Business Overview
 Table 112. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product
 Table 114. Mylan Pharms Inc. Recent Developments/Updates
 Table 115. Bulat Pharmaceutical Company Information
 Table 116. Bulat Pharmaceutical Description and Business Overview
 Table 117. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product
 Table 119. Bulat Pharmaceutical Recent Developments/Updates
 Table 120. MSN Laboratories Company Information
 Table 121. MSN Laboratories Description and Business Overview
 Table 122. MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. MSN Laboratories Gastrointestinal Stromal Tumor Drug Product
 Table 124. MSN Laboratories Recent Developments/Updates
 Table 125. Vannsh Life Sciences Company Information
 Table 126. Vannsh Life Sciences Description and Business Overview
 Table 127. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product
 Table 129. Vannsh Life Sciences Recent Developments/Updates
 Table 130. Beacon Pharmaceuticals Company Information
 Table 131. Beacon Pharmaceuticals Description and Business Overview
 Table 132. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
 Table 134. Beacon Pharmaceuticals Recent Developments/Updates
 Table 135. Drug International Company Information
 Table 136. Drug International Description and Business Overview
 Table 137. Drug International Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 138. Drug International Gastrointestinal Stromal Tumor Drug Product
 Table 139. Drug International Recent Developments/Updates
 Table 140. Deciphera Pharmaceuticals Company Information
 Table 141. Deciphera Pharmaceuticals Description and Business Overview
 Table 142. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 143. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
 Table 144. Deciphera Pharmaceuticals Recent Developments/Updates
 Table 145. CSPC Pharmaceuticals Company Information
 Table 146. CSPC Pharmaceuticals Description and Business Overview
 Table 147. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 148. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
 Table 149. CSPC Pharmaceuticals Recent Developments/Updates
 Table 150. Hansoh Pharmaceuticals Company Information
 Table 151. Hansoh Pharmaceuticals Description and Business Overview
 Table 152. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 153. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
 Table 154. Hansoh Pharmaceuticals Recent Developments/Updates
 Table 155. Kelun Pharmaceuticals Company Information
 Table 156. Kelun Pharmaceuticals Description and Business Overview
 Table 157. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 158. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
 Table 159. Kelun Pharmaceuticals Recent Developments/Updates
 Table 160. Zai Lab Company Information
 Table 161. Zai Lab Description and Business Overview
 Table 162. Zai Lab Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 163. Zai Lab Gastrointestinal Stromal Tumor Drug Product
 Table 164. Zai Lab Recent Developments/Updates
 Table 165. CStone Pharmaceuticals Company Information
 Table 166. CStone Pharmaceuticals Description and Business Overview
 Table 167. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 168. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product
 Table 169. CStone Pharmaceuticals Recent Developments/Updates
 Table 170. China Biopharmaceuticals Company Information
 Table 171. China Biopharmaceuticals Description and Business Overview
 Table 172. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 173. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product
 Table 174. China Biopharmaceuticals Recent Developments/Updates
 Table 175. Key Raw Materials Lists
 Table 176. Raw Materials Key Suppliers Lists
 Table 177. Gastrointestinal Stromal Tumor Drug Distributors List
 Table 178. Gastrointestinal Stromal Tumor Drug Customers List
 Table 179. Gastrointestinal Stromal Tumor Drug Market Trends
 Table 180. Gastrointestinal Stromal Tumor Drug Market Drivers
 Table 181. Gastrointestinal Stromal Tumor Drug Market Challenges
 Table 182. Gastrointestinal Stromal Tumor Drug Market Restraints
 Table 183. Research Programs/Design for This Report
 Table 184. Key Data Information from Secondary Sources
 Table 185. Key Data Information from Primary Sources
 Table 186. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Gastrointestinal Stromal Tumor Drug
 Figure 2. Global Gastrointestinal Stromal Tumor Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Gastrointestinal Stromal Tumor Drug Market Share by Type: 2023 & 2030
 Figure 4. Imatinib Product Picture
 Figure 5. Sunitinib Product Picture
 Figure 6. Regorafenib Product Picture
 Figure 7. Ripretinib Product Picture
 Figure 8. Others Product Picture
 Figure 9. Global Gastrointestinal Stromal Tumor Drug Market Value by Application (2024-2030) & (US$ Million)
 Figure 10. Global Gastrointestinal Stromal Tumor Drug Market Share by Application: 2023 & 2030
 Figure 11. Hospital
 Figure 12. Clinic
 Figure 13. Others
 Figure 14. Global Gastrointestinal Stromal Tumor Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 15. Global Gastrointestinal Stromal Tumor Drug Market Size (2019-2030) & (US$ Million)
 Figure 16. Global Gastrointestinal Stromal Tumor Drug Sales (2019-2030) & (K Units)
 Figure 17. Global Gastrointestinal Stromal Tumor Drug Average Price (US$/Unit) & (2019-2030)
 Figure 18. Gastrointestinal Stromal Tumor Drug Report Years Considered
 Figure 19. Gastrointestinal Stromal Tumor Drug Sales Share by Manufacturers in 2023
 Figure 20. Global Gastrointestinal Stromal Tumor Drug Revenue Share by Manufacturers in 2023
 Figure 21. Global 5 and 10 Largest Gastrointestinal Stromal Tumor Drug Players: Market Share by Revenue in Gastrointestinal Stromal Tumor Drug in 2023
 Figure 22. Gastrointestinal Stromal Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 23. Global Gastrointestinal Stromal Tumor Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 24. North America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2019-2030)
 Figure 25. North America Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2019-2030)
 Figure 26. United States Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 27. Canada Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. Europe Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2019-2030)
 Figure 29. Europe Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2019-2030)
 Figure 30. Germany Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. France Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. U.K. Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Italy Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. Russia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Asia Pacific Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2019-2030)
 Figure 36. Asia Pacific Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2019-2030)
 Figure 37. China Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Japan Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. South Korea Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. India Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Australia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. China Taiwan Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Southeast Asia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Latin America Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2019-2030)
 Figure 45. Mexico Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Brazil Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Argentina Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Colombia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2019-2030)
 Figure 50. Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue Market Share by Country (2019-2030)
 Figure 51. Turkey Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. Saudi Arabia Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 53. UAE Gastrointestinal Stromal Tumor Drug Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 54. Global Sales Market Share of Gastrointestinal Stromal Tumor Drug by Type (2019-2030)
 Figure 55. Global Revenue Market Share of Gastrointestinal Stromal Tumor Drug by Type (2019-2030)
 Figure 56. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Type (2019-2030)
 Figure 57. Global Sales Market Share of Gastrointestinal Stromal Tumor Drug by Application (2019-2030)
 Figure 58. Global Revenue Market Share of Gastrointestinal Stromal Tumor Drug by Application (2019-2030)
 Figure 59. Global Gastrointestinal Stromal Tumor Drug Price (US$/Unit) by Application (2019-2030)
 Figure 60. Gastrointestinal Stromal Tumor Drug Value Chain
 Figure 61. Gastrointestinal Stromal Tumor Drug Production Process
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed

The global Gastrointestinal Stromal Tumor Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Gastrointestinal Stromal Tumor Drug include Novartis, Bayer Pharmaceuticals, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals, Actavis Generics, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., Apotex Inc., Mylan Pharms Inc., Bulat Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Gastrointestinal Stromal Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Stromal Tumor Drug.

The Gastrointestinal Stromal Tumor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Gastrointestinal Stromal Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. 
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Gastrointestinal Stromal Tumor Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gastrointestinal Stromal Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3:  Sales, revenue of Gastrointestinal Stromal Tumor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.